# A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis (Liberty-AD-HAFT)

> **NCT04417894** · PHASE3 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 133 (actual)

## Conditions studied

- Moderate to Severe Atopic Hand and Foot Dermatitis

## Interventions

- **DRUG:** dupilumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04417894
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-14
- **Primary completion:** 2022-08-31
- **Final completion:** 2022-11-23
- **Target enrollment:** 133 (ACTUAL)
- **Last updated:** 2023-12-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04417894

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04417894, "A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis (Liberty-AD-HAFT)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04417894. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*